REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805
Reg.Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059
info@remediumlifecare.com
+91 8433895251

14th November, 2025

To,
BSE LIMITED
P J Towers
Dalal Street, Fort,
Mumbai 400 001

Scrip Code: 539561

Dear Sir/Madam,

Ref.: Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015
Sub.: Outcome of Board meeting held on Friday, 14th November, 2025

We wish to inform you that, the Board of Directors of the Company, at its meeting held today, **Friday, 14th November, 2025** has *inter- alia* considered, approved and taken on record:

1. The Un-Audited Financial Results (Standalone and consolidated) of the Company for the quarter and half year ended September 30, 2025 along with Cash Flow Statement and Statement of Assets and Liabilities as on that date is annexed herewith as **Annexure-I.**

2. *Limited Review Report on the said results received from the Statutory Auditors of the Company.*

Please find enclosed herewith the Summarized Un-Audited Financial Results (Standalone and consolidated) for the for the quarter and half year ended September 30, 2025 and Limited Review Report on the said results for your kind information and records. Extract of Un-Audited financial results (Standalone and consolidated) would also be published in one English and one vernacular newspaper as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Declaration of Non applicability of Regulation 32

Declaration of Non applicability of Regulation 32 of the SEBI (LODR) Regulations, 2015 (Statement of Deviation or Variation as utilisation of proceeds of Rights Issue was done in previous quarter ended i.e. June 30, 2025 and the details of which were filed with the exchange as per requirement of exchange.

REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805
Reg.Office : Office No.9, K Raheja Prime Sagbaug Road, Marol, Andheri (East), Mumbai - 400059
info@remediumlifecare.com
+91 8433895251

The aforesaid Financial Results will be made available on the Company's website at www.remlife.com

Board Meeting commenced at 12.30 p.m. and concluded at 02.30 p.m.

Kindly take the above information on your record and acknowledge.

For **REMEDIUM LIFECARE LIMITED**

REMEDIUM LIFECARE LIMITED MUMBAI

Adarsh Munjal
Whole Time Director
DIN.: 07304004
Encl.: A/a

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West, Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY UNAUDITED FINANCIAL RESULTS OF REMEDIUM LIFECARE LIMITED PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED).

To,
The Board of Directors
Remedium Lifecare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Remedium Lifecare Limited** (('the Company') for the quarter ended 30th September, 2025 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended, including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

TAORI SANDEEP & ASSOCIATES
FIRM REG No. 007414C
CHARTERED ACCOUNTANTS

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
FRN: 007414C

SANDEEP & ASSOCIATES TAORI FIRM REG. No. 007414C CHARTERED ACCOUNTANTS

Atul Jain
Partner
M. No. 048920
UDIN: 25048920BMNQOZ7833

Place: Mumbai
Date: 14th November,2025

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025

(₹ in Lakhs Except per share data)

Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30th September, 2025	30th June, 2025	30th September, 2024	30th September, 2025	30th September, 2024	31st March, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	857.79	1,837.37	2,508.15	2,695.16	10,277.77	22,249.76
II. Other Income	325.24	347.68	82.22	672.92	271.26	1,080.26
III. Total Income (I +II)	**1,183.04**	**2,185.05**	**2,590.38**	**3,368.08**	**10,549.03**	**23,330.02**
IV. Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchases of Stock-in-trade	590.88	1,281.32	11,539.30	1,872.20	26,557.25	35,225.68
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	244.66	613.99	-9,643.85	858.65	-17,053.99	-13,614.71
Employee Benefits Expenses	19.07	19.60	23.79	38.66	46.04	75.60
Finance Costs	18.72	-36.49	281.17	-17.76	281.17	528.86
Depreciation and amortisation expenses	0.03	0.01	0.97	0.04	1.93	3.87
Other Expenses	302.29	343.13	143.10	645.41	244.08	744.26
Total Expenses (IV)	**1,175.66**	**2,221.55**	**2,344.47**	**3,397.21**	**10,076.47**	**22,963.56**
V. Profit/(Loss) before exceptional items and tax (III- IV)	**7.38**	**-36.51**	**245.91**	**-29.12**	**472.56**	**366.46**
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (V-VI)	**7.38**	**-36.51**	**245.91**	**-29.12**	**472.56**	**366.46**
VIII. Tax Expense						
(1) Current tax	-	-	68.41	-	157.76	214.17
(2) Deferred tax	-	-	-	-	-	-0.91
(3) Previous Year Tax	-	-	-	-	-	-
Total Tax	-	-	68.41	-	157.76	213.26
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	**7.38**	**-36.51**	**177.50**	**-29.12**	**314.80**	**153.20**
X. Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI. Tax expense of discontinued operations	-	-	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	**7.38**	**-36.51**	**177.50**	**-29.12**	**314.80**	**153.20**
XIV. Other Comprehensive Income	-	-	-	-	-	-
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	**7.38**	**-36.51**	**177.50**	**-29.12**	**314.80**	**153.20**
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	0.00	0.00	1.76	-0.01	0.08	0.04
(2) Diluted	0.00	0.00	1.76	-0.01	0.08	0.04

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 14th November, 2025. The Statutory Auditors have carried out a "Limited Review" of the Financial results for the Quarter and Half Year ended 30th September,2025.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification

(5) Balance of Receivables and Payables, including borrowings taken, loans & advances given, payable to vendors, security deposits given, other advances given, other liabilities, investments, stock in trade, CWIP and other assets, advances from customers, etc, are subject to confirmation and consequent reconciliation and adjustments, if any. Hence, the effect thereof, on Profit/ Loss, Assets and Liabilities, if any, is not ascertainable, which may be considerable. The Board of the Directors has established a procedure controls to review the reconciliation and recoverability of all the assets and payability of all the liabilities, on a regular basis, based on the formal/ informal agreements/ arrangements with the respective parties involved. As per the opinion of the Board, there will be no substantial impact on their reconciliation with their balance confirmations as on the reporting date.

(6) As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

For Remedium Lifecare Limited

REMEDIUM LIFECARE LIMITED MUMBAI

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004

Place : Mumbai
Date: 14.11.2025

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Unaudited Statement of Standalone Assets and Liabilities as on 30th September,2025

(₹ in Lakhs)

Particulars	As at 30th September, 2025	As at 31st March, 2025
	(Unaudited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	583.22	0.83
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intengible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets -		
(i) Investments	867.26	6.51
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	3.58	3.58
(j) Other non-current assets	-	-
Sub-total Non Current Assets	**1,454.05**	**10.92**
Current Assets		
(a) Inventories	26,079.12	26,937.77
(b) Financials Assets		
(i) Investments		-
(ii) Trade receivables	56,533.36	59,091.77
(iii) Cash and cash equivalents	28.20	28.15
(iv) Bank Balance other than (iii) above	97.74	108.23
(v) Loans/Advances	68,509.92	67,537.73
(vi) Others (to be specified)	-	-
(c) Current tax Assets	-	-
(d) Other current Assets	229.30	250.30
Sub-total - Current Assets	**1,51,477.63**	**1,53,953.94**
TOTAL ASSETS	**1,52,931.68**	**1,53,964.86**

EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	8,819.90	4,032.00
(b) Other Equity	265.28	297.51
Sub Total Equity	**9,085.18**	**4,329.51**
Liabliaties		
Non -Current liabilites		
(a) Financials Liablities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial liablities (other than specified in item (b) to be specified		-
(b) Provisions		-
(c) Deffered Tax Liabilites (net)	-	-
(d) Other Non-Current Liablities	-	-
Sub Total Non Current Liabilities	**-**	**-**
Current Liablities		-
(a) Financials Liablities		
(i) Borrowings	1,08,754.82	1,14,139.31
(ii) Trade Payables	31,979.79	32,098.04
(iii) Other Financial liablities (other than specified in item (c) tobe specified	-	-
(b) Other current liabilities	2,878.06	3,171.79
(c) provisions	233.83	226.20
(d) Current Tax Liablitries	-	-
Sub Total Non Current Liabilities	**1,43,846.50**	**1,49,635.34**
TOTAL EQUITY AND LIABILITES	**1,52,931.68**	**1,53,964.86**

On Behalf of the Board
For REMEDIUM LIFECARE LIMITED

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004
Place:Mumbai
Date: 14.11.2025

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Unaudited Standalone Cashflow Statement for the Year ended on 30th September,2025

(₹ in Lakhs)

Particulars	*LF*	*As at 30.09.2025*		*As at 31.03.2025*	
A. Cashflow from operating activity					
Net Profit / (Loss) before extraordinary items and tax		-29.12		366.46	
Adjustments for:					
Depreciation and amortisation		0.04		3.87	
Profit on sale of FA		-		-	
Finance Cost		-17.76		528.86	
Interest Income		-		-12.89	
Operating profit / (loss) before working capital changes			**-46.84**		**886.30**
Changes in working capital:					
Adjustments for (increase) / decrease in operating assets:					
Inventories		858.65		-13,614.71	
Trade receivables		2,558.41		32,968.41	
Other Current assets		21.01		-39.13	
Current Loans and Advances		-972.19		21,215.89	
Non Current Loans					
Adjustments for increase / (decrease) in operating liabilities:					
Trade payables		-118.25		-39,130.75	
Other current liabilities		-293.73		-1,08,498.29	
Current provisions		7.63		-1,601.25	
Current Tax liabilities					
Cashflow from extraordinary activity					
Cash Generated from operation			**2,061.52**		**-1,08,699.84**
Net Income tax paid			3.12		49.06
Net cash flow from / (used in) operating activities(A)			**2,058.41**		**-1,08,748.90**
B. Cash flow from investing activities					
Capital expenditure on fixed assets, including capital advances					
Investment in Subsidiary		-860.75		-6.51	
Proceeds from sale of fixed assets		-582.43			
Receipt of Loans & Advances					
Interest received		-		12.89	
-- Others					
Cash flow from extraordinary items			-1,443.18		6.38
Net cash flow from / (used in) investing activities (B)					
C. Cash flow from financing activities					
Proceeds from issue of equity shares		4,787.90		-	
Proceeds from Short-term borrowings		-		1,08,369.06	
Payment from Short-term borrowings		-5,384.49		-	
Finance cost		17.76		-528.86	
Loan From Director		-		-	
Dividends paid		-		-	
Tax on dividend		-		-	
Net cash flow from / (used in) financing activities (C)			**-578.83**		**1,07,840.20**
Net Cash flow during the period			-10.44		-16.01
Cash and cash equivalents at the beginning of the year			136.38		152.39

Cash and cash equivalents at the end of the year			125.94		136.38
Reconciliation of Cash and cash equivalents with the Balance Sheet:					
Cash and cash equivalents as per Balance Sheet			125.94		136.38
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"					
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")			125.94		136.38
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)					
Cash and cash equivalents at the end of the year *			125.94		136.38
* Comprises					
(a) Cash on hand			28.20		28.15
(b) Cheques, drafts on hand					
(c) Balances with banks					
(i) In current accounts			97.74		108.23
(ii) In EEFC accounts			-		-
(iii) In deposit accounts with original maturity of			-		-
less than 3 months			-		-
(iv) In earmarked accounts (give details) (Refer			-		-
Note (ii) below)			-		-
(d) Others (specify nature)			-		-
(e) Current investments considered as part of Cash			-		-
and cash equivalents			-		-
			-		-
Total			**125.94**		**136.38**

On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED

ADARSH MUNJAL
WHOLE TIME DIRECTOR
DIN : 07304004

Place: Mumbai
Date: 14.11.2025

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West. Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

INDEPENDENT AUDITOR'S REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF REMEDIUM LIFECARE LIMITED ("the Parent") FOR THE QUARTER ENDED SEPTEMBER 30,2025 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To,
The Board of Directors
Remedium Lifecare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Remedium Lifecare Limited (hereinafter referred as to as "the Holding Company") and its subsidiary (Holding Company and its Subsidiary together referred to as "the Group") for the year ended September 30, ,2025 ('the statement") attached herewith , being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

   Remlife Global PTE

TAORI SANDEEP & ASSOCIATES
FIRM REG No. 007414C
CHARTERED ACCOUNTANTS

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West. Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

5. Based on review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below , nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principle laid down in the aforesaid Indian Accounting Standard (Ind AS) Specified under Section 133 of the Companies Act,2013 as amended, read with relevant rule issued thereunder and other accounting principle generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulations 33 of the Listing Regulations, including the matter in which is to be disclosed , or that it contained any material misstatement.

6. The accompanying statement includes the unaudited interim Standalone financial results/financial information, in respect of-

   a. One Subsidiary , whose unaudited interim standalone financial statement/ financial information reflect total Revenue of Rs. 1,02,48,02,290/- for the quarter ended 30th September,2025 , total profit after tax of Rs. 8,54,95,526/- for the quarter ended 30th September,2025 and total comprehensive income of Rs. 8,54,95,526/- for the quarter ended 30th September,2025, as considered in the statement.

   This unaudited interim standalone financial results/ financial information has not been reviewed by their auditor and have been approved and furnished to us by the management and our conclusion on the statement, in so far it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such unaudited interim standalone financial results/ financial information. According to the information and explanations given to us by the management, this unaudited interim standalone financial results/ financial information is not material to Group.

   Our Conclusion on the statement is not modified in respect of our reliance on the unaudited interim standalone financial results/ financial information certified by the management.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
FRN: 007414C

TAORI SANDEEP & ASSOCIATES * FIRM REG No. 007414C CHARTERED ACCOUNTANTS *

Atul

Atul Jain
Partner
M. No. 048920
UDIN: 25048920BMNQPA6257

Place: Mumbai
Date: 14th November,2025

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025

(₹ in Lakhs Except per share data)

Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30th September, 2025	30th June, 2025	30th September, 2024	30th September, 2025	30th September, 2024	31st March, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	11,105.82	11,336.67	-	22,442.49	-	40,525.11
II. Other Income	325.43	347.68	-	673.12	-	1,080.26
III. Total Income (I +II)	**11,431.25**	**11,684.35**	-	**23,115.61**	-	**41,605.37**
IV. Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchases of Stock-in-trade	9,802.59	10,169.14	-	19,971.73	-	53,428.22
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	244.66	613.99	-	858.65	-	-13,614.71
Employee Benefits Expenses	19.07	19.60	-	38.66	-	75.60
Finance Costs	18.72	-36.49	-	-17.76	-	528.86
Depreciation and amortisation expenses	0.03	0.01	-	0.04	-	3.87
Other Expenses	302.49	346.87	-	649.36	-	745.09
Total Expenses (IV)	**10,387.56**	**11,113.12**	-	**21,500.68**	-	**41,166.93**
V. Profit/(Loss) before exceptional items and tax (III- IV)	**1,043.69**	**571.23**	-	**1,614.92**	-	**438.44**
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (V-VI)	**1,043.69**	**571.23**	-	**1,614.92**	-	**438.44**
VIII. Tax Expense						
(1) Current tax	181.35	106.35	-	287.71	-	226.40
(2) Deferred tax	-	-	-	-	-	-0.91
(3) Previous Year Tax	-	-	-	-	-	-
Total Tax	181.35	106.35	-	287.71	-	225.50
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	**862.34**	**464.88**	-	**1,327.22**	-	**212.94**
X. Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI. Tax expense of discontinued operations	-	-	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	**862.34**	**464.88**	-	**1,327.22**	-	**212.94**
XIV. Other Comprehensive Income	-	-	-	-	-	-
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	**862.34**	**464.88**	-	**1,327.22**	-	**212.94**
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	0.10	0.05	-	0.15	0.00	0.05
(2) Diluted	0.10	0.05	-	0.15	0.00	0.05

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 14th November, 2025. The Statutory Auditors have carried out a "Limited Review" of the Financial results for the Quarter and Half Year ended 30th September,2025.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification

(5) Balance of Receivables and Payables, including borrowings taken, loans & advances given, payable to vendors, security deposits given, other advances given, other liabilities, investments, stock in trade, CWIP and other assets, advances from customers, etc, are subject to confirmation and consequent reconciliation and adjustments, if any. Hence, the effect thereof, on Profit/ Loss, Assets and Liabilities, if any, is not ascertainable, which may be considerable. The Board of the Directors has established a procedure controls to review the reconciliation and recoverability of all the assets and payability of all the liabilities, on a regular basis, based on the formal/ informal agreements/ arrangements with the respective parties involved. As per the opinion of the Board, there will be no substantial impact on their reconciliation with their balance confirmations as on the reporting date.

(6) As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

For Remedium Lifecare Limited

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004

Place : Mumbai
Date: 14.11.2025

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Unaudited Statement of Consolidated Assets and Liabilities as on 30th September,2025

(₹ in Lakhs)

Particulars	As at 30th September, 2025	As at 31st March, 2025
	(Unaudited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	583.22	0.83
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intengible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets -		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	3.58	3.58
(j) Other non-current assets	-	-
Sub-total Non Current Assets	**586.80**	**4.41**
Current Assets		
(a) Inventories	26,079.12	26,937.77
(b) Financials Assets		
(i) Investments		-
(ii) Trade receivables	66,781.38	77,161.98
(iii) Cash and cash equivalents	28.20	28.15
(iv) Bank Balance other than (iii) above	103.39	114.57
(v) Loans/Advances	68,509.92	67,537.73
(vi) Others (to be specified)	-	-
(c) Current tax Assets	-	-
(d) Other current Assets	229.30	250.30
Sub-total - Current Assets	**1,61,731.30**	**1,72,030.49**
TOTAL ASSETS	**1,62,318.10**	**1,72,034.90**

EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	8,819.90	4,032.00
(b) Other Equity	1,699.96	357.11
Sub Total Equity	**10,519.86**	**4,389.11**
Liabliaties		
Non -Current liabilites		
(a) Financials Liablities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial liablities (other than specified in item (b) to be specified		-
(b) Provisions		-
(c) Deffered Tax Liabilites (net)	-	-
(d) Other Non-Current Liablities	-	-
Sub Total Non Current Liabilities	**-**	**-**
Current Liablities		-
(a) Financials Liablities		
(i) Borrowings	1,08,754.82	1,14,139.31
(ii) Trade Payables	39,643.27	50,096.26
(iii) Other Financial liablities (other than specified in item (c) tobe specified	-	-
(b) Other current liabilities	2,878.06	3,171.79
(c) provisions	522.08	238.44
(d) Current Tax Liablitries	-	-
Sub Total Non Current Liabilities	**1,51,798.23**	**1,67,645.80**
TOTAL EQUITY AND LIABILITES	**1,62,318.10**	**1,72,034.90**

On Behalf of the Board
For REMEDIUM LIFECARE LIMITED

REMEDIUM LIFECARE LIMITED MUMBAI

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004
Place:Mumbai
Date: 14.11.2025

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Unaudited Consolidated Cashflow Statement for the Year ended on 30th September,2025

(₹ in Lakhs)

Particulars	LF	As at 30.09.2025		As at 31.03.2025	
A. Cashflow from operating activity					
Net Profit / (Loss) before extraordinary items and tax		1,327.22		366.46	
Adjustments for:					
Depreciation and amortisation		0.04		3.87	
Profit on sale of FA		-		-	
Finance Cost		-17.76		528.86	
Interest Income		-		-12.89	
Operating profit / (loss) before working capital changes			**1,309.50**		**886.30**
Changes in working capital:					
Adjustments for (increase) / decrease in operating assets:					
Inventories		858.65		-13,614.71	
Trade receivables		10,399.35		32,968.41	
Other Current assets		21.01		-39.13	
Current Loans and Advances		-972.19		21,215.89	
Non Current Loans					
Adjustments for increase / (decrease) in operating liabilities:					
Trade payables		-10,452.99		-39,130.75	
Other current liabilities		-293.73		-1,08,498.29	
Current provisions		283.65		-1,601.25	
Current Tax liabilities					
Cashflow from extraordinary activity					
Cash Generated from operation			**-156.26**		**-1,08,699.84**
Net Income tax paid			3.12		49.06
Net cash flow from / (used in) operating activities(A)			**-159.38**		**-1,08,748.90**
B. Cash flow from investing activities					
Capital expenditure on fixed assets, including capital advances					
Investment in Subsidiary		-		-6.51	
Proceeds from sale of fixed assets		-582.43			
Receipt of Loans & Advances					
Interest received		-		12.89	
-- Others					
Cash flow from extraordinary items			-582.43		6.38
Net cash flow from / (used in) investing activities (B)					
C. Cash flow from financing activities					
Proceeds from issue of equity shares		4,787.90		-	
Proceeds from Short-term borrowings		-		1,08,369.06	
Payment from Short-term borrowings		-5,384.49		-	
Finance cost		17.76		-528.86	
Loan From Director		-		-	
Dividends paid		-		-	
Tax on dividend		-		-	
Net cash flow from / (used in) financing activities (C)			**-578.83**		**1,07,840.20**
Net Cash flow during the period			-11.13		-16.01
Cash and cash equivalents at the beginning of the year			142.72		152.39
Cash and cash equivalents at the end of the year			131.59		136.38

Reconciliation of Cash and cash equivalents with the Balance Sheet:					
Cash and cash equivalents as per Balance Sheet			131.59		136.38
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"					
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")			131.59		136.38
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)					
Cash and cash equivalents at the end of the year *			131.59		136.38
* Comprises					
(a) Cash on hand			28.20		28.15
(b) Cheques, drafts on hand					
(c) Balances with banks					
(i) In current accounts			103.39		114.57
(ii) In EEFC accounts			-		-
(iii) In deposit accounts with original maturity of			-		-
less than 3 months			-		-
(iv) In earmarked accounts (give details) (Refer			-		-
Note (ii) below)			-		-
(d) Others (specify nature)			-		-
(e) Current investments considered as part of Cash			-		-
and cash equivalents			-		-
			-		-
Total			**131.59**		**142.72**

On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED

ADARSH MUNJAL
WHOLE TIME DIRECTOR
DIN : 07304004

Place: Mumbai
Date: 14.11.2025